Positron Emission Radiometals 64Cu, 68Ga, 86Y and 89Zr Labeled PET Drugs

doi:10.7538/tws.2017.30.01.0078

Abstract

Abstract:

Positron emission radiometals ⁶⁴Cu, ⁶⁸Ga, ⁸⁶Y and ⁸⁹Zr have different half lives and special biological properties, not only enrich the diversity of PET drugs, but also provide a new opportunity for the diagnosis and treatment of disease. In recent years, positron emission radiometals ⁶⁴Cu, ⁶⁸Ga, ⁸⁶Y and ⁸⁹Zr have more and more applications in the medical diagnostics of PET (positron emission tomography). ⁶⁴Cu has already had a significant impact in cancer hypoxia imaging. ⁶⁸Ga is developing rapidly in the field of diagnosis of NET (Neuroendocrine tumor) tumor. ⁸⁹Zr and ⁸⁶Y are expected to play a role in the field of immunoPET and radioimmunotheray. This paper briefly reviews the research progress on the production and purification, solution coordination chemistry and applications of ⁶⁸Ga, ⁸⁶Y, ⁸⁹Zr and ⁶⁴Cu.

Key words: positron emission tomography, ⁶⁴Cu, ⁶⁸Ga, ⁸⁶Y, ⁸⁹Zr, coordination chemistry, clinical application

摘要：

⁶⁴Cu，⁶⁸Ga，⁸⁶Y和⁸⁹Zr具备不同的半衰期和特殊生物体内性质，丰富了PET药物的多样性，为疾病的诊断和治疗提供了新的契机。近年来，金属正电子核素⁶⁴Cu，⁶⁸Ga，⁸⁶Y和⁸⁹Zr标记的药物在正电子发射计算机断层显像（PET）诊断中的应用越来越多，⁶⁴Cu在乏氧显像中发挥重要作用，⁶⁸Ga在靶向神经内分泌(NET)类肿瘤的诊断药物领域发展迅速，⁸⁶Y，⁸⁹Zr有望在免疫PET和放射免疫治疗领域发挥作用。本文主要综述金属正电子核素⁶⁴Cu，⁶⁸Ga，⁸⁶Y ，⁸⁹Zr的生产与纯化，溶液配位化学以及应用方面的研究进展。

关键词: 正电子发射计算机断层显像（PET）, ⁶⁴Cu, ⁶⁸Ga, ⁸⁶Y, ⁸⁹Zr, 配位化学, 临床应用

CHEN Wen;WEI Hong-yuan;ZHOU Zhi-jun;LUO Shun-zhong. Positron Emission Radiometals ⁶⁴Cu, ⁶⁸Ga, ⁸⁶Y and ⁸⁹Zr Labeled PET Drugs[J]. Journal of Isotopes, 2017, 30(1): 78-88.

陈文;魏洪源;周志军;罗顺忠. 金属正电子核素⁶⁴Cu，⁶⁸Ga，⁸⁶Y和⁸⁹Zr的PET标记药物研究进展[J]. 同位素, 2017, 30(1): 78-88.

References

［1］Wadas T J, Wong E H, Weisman G R, et al. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease［J］. Chem Rev, 2010, 110(5): 2858-2902.
［2］Correia J D, Paulo A, Raposinho P D, et al. Radiometallated peptides for molecular imaging and targeted therapy［J］. Dalton Trans., 2011, 40(23): 6144-6167.
［3］Zeglis B M, Houghton J L, Evans M J, et al. Underscoring the in fluence of inorganic chemistry on nuclear imaging with radiometals［J］. Inorg. Chem, 2014, 53: 1880-1899.
［4］Price E W, Orvig C.Matching chelators to radiometals for radiopharmaceuticals［J］. Chem. Soc. Rev., 2014, 43(1): 260-290.
［5］Price T W, Greenman J, Stasiuk G J. Current advances in ligand design for inorganic positron emission tomography tracers ⁶⁸Ga, ⁶⁴Cu, ⁸⁹ Zr and ⁴⁴Sc［J］. Dalt. Trans., 2016, 40(45): 147.
［6］Zinn K R, Chaudhuri T R, Cheng T P,et al. Production of no-carrier-added ⁶⁴Cu from zinc metal irradiated under boron shielding［J］. Cancer, 1994, 73(3 Suppl): 774-778.
［7］Kim J Y, Park H, Lee J C, et al.A simple Cu-64 production and its application of Cu-64 ATSM［J］. Appl. Radiat. Isot., 2009, 67(7-8):1 190-1194.
［8］Obata A, Kasamatsu S, McCarthy D W, et al.Production of therapeutic quantities of ⁶⁴Cu using a 12 MeV cyclotron［J］. Nucl. Med. Biol., 2003, 30(5): 535-539.
［9］Kozempel J, Abbas K, Simonelli F, et al. A novel method for n.c.a. ⁶⁴Cu production by the ⁶⁴Zn(d, 2p) ⁶⁴Cu reaction and dual ion-exchange column chromatography［J］. Radiochim Acta, 2007, 95(2): 75-80.
［10］Zhernosekov K P, D Filosofov V, Baum R P,et al. Processing of generator produced ⁶⁸Ga for medical application［J］. J. Nucl. Med., 2007, 48(10): 1741-1748.
［11］Yoo J, Tang L, Perkins T, et al. Preparation of high specific activity ⁸⁶Y using a small biomedical cyclotron［J］.Nucl. Med. Biol., 2005, 32(8): 891-897.
［12］Dejesus O T , Nickles R J.Production and purification of ⁸⁹Zr, a potential PET antibody label［J］. Int. J. Rad. Appl. Instrum. A.,1990, 41(8): 789-790.
［13］Woodin K S, Heroux K J, Boswell C A, et al. Kinetic inertness and electrochemical behavior of copper(Ⅱ) tetraazamacrocyclic complexes: Possible implications for in vivo stability［J］.Eur. J. Inorg. Chem., 2005(23): 4829-4833.
［14］Wood K A, Wong W L, Saunders M I.［⁶⁴Cu］diacetyl-bis(N4-methyl-thiosemicarbazone)-a radiotracer for tumor hypoxia［J］.Nucl. Med. Biol., 2008, 35(4): 393-400.
［15］Ribot E J, Thiaudière E, Roulland R, et al.Application of MRI phase-difference mapping to assessment of vascular concentrations of BMS agent in mice［J］. Contrast Media Mol. Imaging, 2008, 3(2): 53-60.
［16］Morfin J F , Tóthé.Kinetics of Ga(NOTA) formation from weak Ga-citrate complexes［J］. Inorg. Chem., 2011, 50(20): 10371-10378.
［17］Singhal A, Toth L M, Lin J S, et al.Zirconium(Ⅳ) tetramer/octamer hydrolysis equilibrium in aqueous hydrochloric acid solution［J］.J. Am. Chem. Soc., 1996, 118(46): 11529-11534.
［18］Meijs W E, Herscheid J D M, Haisma H J, et al.Evaluation of desferal as a bifunctional chelating agent for labeling antibodies with Zr-89［J］. Int. J. Radiat, 1992, 43(12): 1443-1447.
［19］Zhai C, Summer D, Rangger C, et al. Novel bifunctional cyclic chelator for (89)Zr labeling-radiolabeling and targeting properties of RGD conjugates［J］. Mol. Pharm.,2015, 12(6):2142-2150.
［20］Patra M, Bauman A, Mari C, et al.An octadentate bifunctional chelating agent for the development of stable zirconium-89 based molecular imaging probes［J］.Chem. Commun. (Camb)., 2014, 50(78): 11523-11525.
［21］Deri M A, Ponnala S, Kozlowski P, et al. P-SCN-Bn-HOPO: A superior bifunctional chelator for ⁸⁹Zr-Immuno PET［J］. Bioconjug. Chem., 2015, 26(12): 2579-2591.
［22］Dearling J L J, Lewis J S, Mullen G E D, et al.Design of hypoxia-targeting radiopharmaceuticals: Selective uptake of copper-64 complexes in hypoxic cells in vitro［J］. Eur. J. Nucl. Med., 1998, 25(7): 788-792.
［23］Dearling J L J, Lewis J S, Mullen G E D, et al.Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: Structure-activity relationships［J］.J. Biol. Inorg. Chem., 2002, 7(3): 249-259.
［24］Lewis J S, McCarthy D W, McCarthy T J, et al.Evaluation of ⁶⁴Cu-ATSM in vitro and in vivo in a hypoxic tumor model［J］. J. Nucl. Med., 1999, 40(1): 177-183.
［25］Maurer R I, Blower P J, Dilworth J R, et al.Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals［J］. J. Med. Chem., 2002, 45(7): 1420-1431.
［26］Castle T C, Maurer R I, Sowrey F E, et al.Hypoxia-targeting copper bis(selenosemicarbazone) complexes: Comparison with their sulfur analogues［J］. J. Am. Chem. Soc., 2003, 125(33): 10040-10049.
［27］Burgman P, O’Donoghue J A, Lewis J S, et al.Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM［J］. Nucl. Med. Biol., 2005, 32(6): 623-630.
［28］Anderson C J, Dehdashti F, Cutler P D, et al. ⁶⁴Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors［J］.J. Nucl. Med., 2001, 42(2): 213-221.
［29］Glaus C, Rossin R, Welch M J, et al.In vivo evaluation of Cu-64-labeled magnetic nanoparticles as a dual-modality PET/MR imaging agent［J］.Bioconjug. Chem., 2010, 21(4): 715-722.
［30］Zhou M, Zhang R, Huang M, et al.A Chelator-Free multifunctional-［⁶⁴Cu］-CuS nanoparticle platform for simultaneous Micro-PET/CT imaging and photothermal ablation therapy［J］.J. Am. Chem. Soc., 2010, 132: 15351-15358.
［31］Peng F, Lu X, Janisse J, et al. PET of human prostate cancer xenografts in mice with increased uptake of ⁶⁴CuCl₂［J］. J. Nucl. Med., 2006, 47(10): 1649-1652.
［32］Peng F, Muzik O, Gatson J, et al. “Assessment of traumatic brain injury by increased ⁶⁴Cu Uptake on ⁶⁴CuCl₂ PET/CT［J］. J. Nucl. Med., 2015, 5(8): 1252-1257.
［33］Virgolini I, Ambrosini V, Bomanji J B, et al. Procedure guidelines for PET/CT tumour imaging with ⁶⁸Ga- DOTA conjugated peptides: ⁶⁸Ga- DOTA-TOC, ⁶⁸Ga- DOTA-NOC, ⁶⁸Ga- DOTA-TATE［J］. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37(10): 2004-2010.
［34］Ambrosini V, Tomassetti P, Castellucci P, et al.Comparison between ⁶⁸Ga- DOTA-NOC and ¹⁸F-DOPA PET for the detection of gastro entero pancreatic and lung neuro-endocrine tumours［J］.Eur. J. Nucl. Med. Mol. Imaging, 2008, 3(8): 1431-1438.
［35］Prasad V, Ambrosini V, Hommann M, et al.Detection of unknown primary neuroendocrine tumours (CUP-NET) using ⁶⁸Ga- DOTA-NOC receptor PET/CT［J］.Eur. J. Nucl. Med. Mol. Imaging, 2010, 37(1): 67-77.
［36］Henze M, Schuhmacher J, Hipp P, et al.PET imaging of somatostatin receptors using ［⁶⁸GA］DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas［J］.J. Nucl. Med., 2001,42, (7): 1053-1056.
［37］Hofmann M, Maecke H, Weckesser E, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand ⁶⁸Ga-DOTATOC: Preliminary data［J］. Eur.J. Nucl. Med., 2001,28, (12): 1751-1757.
［38］Kowalski J. Evaluation of positron emission tomography imaging using ［⁶⁸Ga］-DOTA-D Phe1-Tyr3-Octreotide in comparison to ［¹¹¹In］-DTPAOC SPECT. First results in patients with neuroendocrine tumors［J］. Mol. Imaging Biol.,2003, 5(1): 42-48.
［39］Buchmann I, Henze M, Engelbrecht S, et al. Comparison of ⁶⁸Ga-DOTATOC PET and ¹¹¹In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours［J］. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34(10): 1617-1626.
［40］Gabriel M, Decristoforo C, Kendler D, et al. ⁶⁸Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT［J］. J. Nucl. Med., 2007, 48(4): 508-518.
［41］Poeppel T D, Binse I, Petersenn S, et al. ⁶⁸Ga-DOTATOC versus ⁶⁸Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors［J］.J Nucl Med, 2011, 52(12): 1864-1870.
［42］Antunes P, Ginj M, Zhang H, et al.Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?［J］.Eur. J. Nucl. Med. Mol. Imaging, 2007, 34(7): 982-993.
［43］Baum R P, Prasad V, Müller D, et al.Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic ¹¹¹In or ⁶⁸Ga-labeled affibody molecules［J］.J. Nucl. Med., 2010, 51(6): 892-897.
［44］Schuhmacher J, Zhang H, Doll J, et al. GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a ⁶⁸Ga-labeled bombesin(6-14) analog［J］. J. Nucl. Med., 2005, 46(4): 691-699.
［45］Vitha T, Kubícˇek V, Hermann P, et al.Lanthanide(Ⅲ) complexes of bis(phosphonate) monoamide analogues［J］. J. Med. Chem., 2008, 51(3): 677-683.
［46］Afshar-Oromieh A, Malcher A, Eder M, et al.PET imaging with a ［⁶⁸Ga］gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions［J］.Eur. J. Nucl. Med. Mol. Imaging, 2013, 40(4): 486-495.
［47］Palm S, Enmon R M, Matei C, et al.Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI［J］. J. Nucl. Med., 2003, 44(7): 1148-1155.
［48］Wiseman G A, Kornmehl E, Leigh B, et al.Radiation dosimetry results and safety correlations from ⁹⁰Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin’s lymphoma: combined data from 4 clinical trials［J］. J. Nucl. Med., 2003, 44: 465-474.
［49］Helisch A, Fórster G J, Reber H, et al.Pre-therapeutic dosimetry and biodistribution of ⁸⁶Y-DOTA Phe1-Tyr3-octreotide versus ¹¹¹In-pentetreotide in patients with advanced neuroendocrine tumours［J］.Eur. J. Nucl. Med. Mol., Imaging, 2004, 31(10): 1386-1392.
［50］Garmestani K, Milenic D E, Plascjak P S, et al.A new and convenient method for purification of ⁸⁶Y using a Sr(Ⅱ) selective resin and comparison of biodistribution of ⁸⁶Y and ¹¹¹In labeled Herceptin［J］. Nucl. Med. Biol., 2002, 29(5): 599-606.
［51］Ulmert D, Evans M J, Holland J P, et al. Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen［J］. Cancer Discov., 2012, 2(4): 320-327.
［52］Garousi J, Andersson K G, Mitran B, et al.PET imaging of epidermal growth factor receptor expression in tumours using ⁸⁹Zr-labelled ZEGFR:2377 affibody molecules［J］. Int. J. Oncol., 2016, 48(4): 1325-1332.
［53］Börjesson P K E, Jauw Y W S, Boellaard R, et al.Performance of immuno positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients［J］. Clin. Cancer Res., 2006, 12(71): 2133-2140.
［54］Muylle K, Flamen P, Vugts D J, et al.Tumour targeting and radiation dose of radioimmunotherapy with ⁹⁰Y-rituximab in CD20+ B-cell lymphoma as predicted by ⁸⁹Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab［J］.Eur. J. Nucl. Med. Mol. Imaging, 2015, 42(8): 1304-1314.
［55］Dijkers E C, Oude Munnink T H, Kosterink J G, et al.Biodistribution of ⁸⁹Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer［J］.Clin. Pharmacol. Ther., 2010, 87(5): 586-592.
［56］Pandit-Taskar N, O’Donoghue J A, Beylergil V, et al. ⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer［J］. Eur. J. Nucl. Med. Mol. Imaging, 2014, 41(11): 2093-2105.

[1]	LI Zhongyong;CUI Haiping. Research Progress of Aβ Targeting PET Imaging Agents for Alzheimer’s Disease [J]. Journal of Isotopes, 2020, 33(1): 27-37.
[2]	ZHU Hua;LIU Teli;WANG Feng;JIANG Jinquan;HAN Xuedi;YANG Zhi. Preparation, Quality Control and Biodistribution Analysis of ⁶⁴Cu Labeled DKFZ-PSMA-617 and its Clinical Translation Research [J]. Journal of Isotopes, 2019, 32(6): 382-387.
[3]	HUANG Qianhuan;XU Yuping;YANG Min. PET Image Developments for HER2-Positive Breast Cancer [J]. Journal of Isotopes, 2019, 32(6): 431-438.
[4]	GUO Zhide;ZHANG Xianzhong;DU Jin. The Research Progress of ⁶⁸Ga Generator and ⁶⁸Ga Radiopharmaceuticals [J]. Journal of Isotopes, 2019, 32(5): 360-374.
[5]	LIU Bingnan;XIONG Liping;JIANG Shende;YAO Shaobo. Synthesis of 16-Epiestriol and its Radiolabeling Procedure [J]. Journal of Isotopes, 2018, 31(5): 283-290.
[6]	MA Jingxin;WU Zhou;JIANG Shende;WANG Hongliang;WU Zhifang. Synthesis and Biological Evaluation of 3-O-(2-¹⁸F-fluoroethyl)-L-DOPA as A Potential PET Agent for Tumor Imaging [J]. Journal of Isotopes, 2018, 31(5): 310-317.
[7]	TIAN Jiale;JIA Hongmei. Current Status and Prospects of ^99mTc-radiopharmaceuticals [J]. Journal of Isotopes, 2018, 31(3): 143-156.
[8]	MA Hui;LIANG Hong;XU Wan-bang;TANG Gang-hua. Progress of PET Imaging Agents for Cardiovascular Diseases [J]. Journal of Isotopes, 2018, 31(2): 114-122.
[9]	DAI Tiantian;WEI Qingyang. Advantages and Disadvantages of the Lutetium-176 Intrinsic Radiation in the PET System [J]. Journal of Isotopes, 2018, 31(1): 26-32.
[10]	LIU Yinli;LI Zhongyong. Preparation of ¹⁸F-Labeled Styryl Nitrogenous Heterocycles [J]. Journal of Isotopes, 2018, 31(1): 33-41.
[11]	HUANG Qian-huan;PAN Dong-hui;XU Yu-ping;SHENG Jie;WANG Yan-ting;YANG Min. Application of the ⁶⁸Ge/⁶⁸Ga Generator in Clinic [J]. Journal of Isotopes, 2017, 30(4): 270-275.
[12]	CHEN Mei-jie;CHEN Song;YIN Ya-fu;LI Ya-ming. The Application of PET/CT in Predicting and Evaluating the Therapeutic Response in Chemotherapy of Solid Tumor [J]. Journal of Isotopes, 2017, 30(2): 148-152.
[13]	ZHANG Zheng-wei;ZHU Jian-hua;YAO Zhi-wen;GUAN Yi-hui;HUA Feng-chun. Modified Auto-synthesis and Clinical Trial of the ¹¹C-PIB as a Potential β-amyloid Imaging Agent [J]. Journal of Isotopes, 2017, 30(1): 23-28.
[14]	YIN Ji-lin;WANG Cheng;WANG Xin-lu. PET Molecular Probes Targeting Folate Receptor [J]. Journal of Isotopes, 2016, 29(3): 184-192.
[15]	TANG Cai-hua;HU Kong-zhen;TANG Gang-hua. Research Progress of PET Traces for Alzheimer’s Disease [J]. Journal of Isotopes, 2014, 27(1): 55-63.

Positron Emission Radiometals ⁶⁴Cu, ⁶⁸Ga, ⁸⁶Y and ⁸⁹Zr Labeled PET Drugs

金属正电子核素⁶⁴Cu，⁶⁸Ga，⁸⁶Y和⁸⁹Zr的PET标记药物研究进展

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics